Gå direkt till huvudinnehållet

Coronavirus: covid-19 (SARS-CoV-2)

Senast uppdaterad: Senast reviderad:


Definition:
Sjukdom orsakad av coronaviruset SARS-CoV-2. 
Förekomst:
Startade i Kina i slutet av 2019. Finns i hela världen. Världskarta uppdaterad förekomst finns hos WHO .
Symtom:
Brett spann, allt från asymtomatiska personer till livshotande symtom. Förkylningssymtom är vanligt förekommande i form av torrhosta, trötthet, feber. I vissa fall andningssvårigheter, muskelvärk, GI-symtom. Bortfall av lukt och smak.
Kliniska fynd:
Brett spektrum, inga fynd till allvarlig andningspåverkan kan ses. Feber och hosta. 
Diagnostik:
PCR kan detektera viruset. Främst nasopharynxprov, svalgprov eller kombinerat.
Behandling:
Majoriteten kan egenvårda hemma med symtomlindring. En andel blir allvarligt sjuka och behöver sjukhusvård med syrgas. Vissa behandlingar tycks förkorta förloppet. Det finns vaccin som verkar skydda mot allvarlig sjukdom.
  1. Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold. JAMA 2020; Epub: Jan 23. Pmid: 31971553 PubMed  
  2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. NEJM 2020; Epub: Jan 24. doi:10.1056/NEJMoa2001017 DOI  
  3. Folkhälsomyndigheten. Bekräftade fall i Sverige – daglig uppdatering. Covid-19 – statistik med diagram och kartor. Hämtad 2020-10-27. experience.arcgis.com  
  4. Guan W, Ni Z, Hu Y et al.Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; (published online Feb 28.)DOI:10.1056/NEJMoa2002032 DOI  
  5. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. Published online March 17, 2020. jamanetwork.com  
  6. Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care. 04 April 2020
  7. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. Published online April 06, 2020. doi:10.1001/jama.2020.5394 DOI  
  8. Ludvigsson JF. Systematic review of COVID‐19 in children show milder cases and a better prognosis than adults. Acta Paediatr. Accepted Author Manuscript. 2020. doi:10.1111/apa.15270 DOI  
  9. Folkhälsomyndigheten. Covid-19. Demografisk beskrivning av bekräftade fall i Sverige 13 mars-7 maj 2020. Artikelnummer: 20096. www.folkhalsomyndigheten.se  
  10. Folkhälsomyndigjeten. Veckorapporter om covid-19. Hämtad 2020-10-27. www.folkhalsomyndigheten.se  
  11. Delamater PL, Street EJ, Leslie TF et al. Complexity of the Basic Reproduction Number (R0). Emerging Infectious Diseases, 25(1), 1-4. 2019. https://dx.doi.org/10.3201/eid2501.171901.
  12. Folkhälsomyndigheten. Serologi för covid-19 En sammanfattning av kunskapsläget avseende antikroppssvar och immunitet för sjukdomen covid-19 orsakad av viruset SARS-CoV-2. Version 3, 2020-06-30. Hämtad 2020-07-10. www.folkhalsomyndigheten.se  
  13. Edridge A, Kaczorowska JM, Hoste A et al. Human coronavirus reinfection dynamics: lessons for SARS-CoV-2.medRxiv 2020.05.11.20086439; doi: https://doi.org/10.1101/2020.05.11.20086439
  14. Glans H, Sönnerborg A, Aleman S. Covid-19 – uppdatering om klinisk bild och behandling, Medicinsk kommentar. Läkartidningen. 2020;117:F3HW lakartidningen.se  
  15. Lundström A, Sandén P. ACE-2 och coronavirus – en fråga om balans och dynamik? Medicinsk kommentar, Läkartidningen. 2020;117:F3S3
  16. Chen L, Zhong L. Genomics functional analysis and drug screening of SARS-CoV-2 published online ahead of print, 2020 Apr 14. Genes Dis. 2020;10.1016/j.gendis.2020.04.002. doi:10.1016/j.gendis.2020.04.002 DOI  
  17. Folkhälsomyndigheten Hämtad 2020-03-17. https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-utbrott/covid-19/information-till-varden/
  18. World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. 29 March 2020. Hämtad 2020-04-03.
  19. Xie X, Li Y, Chwang ATY, Ho PL and Seto WH. How far droplets can move in indoor environments – revisiting the Wells evaporation–falling curve. Indoor Air, 17: 211-225. 2007. doi:10.1111/j.1600-0668.2007.00469.x DOI  
  20. van Doremalen N, Morris DH, Holbrook MG et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. March 17, 2020 DOI: 10.1056/NEJMc2004973 DOI  
  21. Chin A, Chu J, Perera M et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet Microbe. Published:April 02, 2020 DOI:https://doi.org/10.1016/S2666-5247(20)30003-3
  22. Wu Y, Guo C, Tang L. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. The Lancet Gastroenterology and Hepatology, correspondence. March 19 2020. Hämtad 2020-03-19. DOI:https://doi.org/10.1016/S2468-1253(20)30083-2
  23. Kaufman B, Whitaker R, Mahendraratnam Lederer N et al. Comparing Associations of State Reopening Strategies with COVID-19 Burden. Springer Nature. publicerad 2020-10-08. Hämtad 2020-10-20. medibas.se  
  24. Ridell S, Goldie S, Hill A et al. The effect of temperature on persistence of SARS-CoV-2 on common surfaces. Virology Journal volume 17, Article number: 145 (2020).
  25. Svenska Barnläkarföreningen, Svenska neonatalföreningen, Svensk förening för Obstetrik och Gynekologi. L Navér, E Nomann, K Pettersson, S Saltvedt. Rekommendation om handläggning av barn till kvinnor med verifierad/sannolik Covid-19. 2020-03-20 www.barnlakarforeningen.se  
  26. Cuicchi D, Lazzarotto T, Poggioli G. Fecal-oral transmission of SARS-CoV-2: review of laboratory-confirmed virus in gastrointestinal system. Int J Colorectal Dis. 2021;36(3):437-444. doi:10.1007/s00384-020-03785-7 DOI  
  27. Han Y, Ma H, Sun M. Clinical manifestation, outcomes in pregnant women with COVID-19 and the possibility of vertical transmission: a systematic review of the current data. Journal of Perinatal Medicine. Volume 48 Issue 9. https://doi.org/10.1515/jpm-2020-0431
  28. Dumitriu D, Emeruwa U, Hanft E. Outcomes of Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection at a Large Medical Center in New York City. JAMA Pediatr. Published online October 12, 2020. doi:10.1001/jamapediatrics.2020.4298 DOI  
  29. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. PMID: 32035997 PubMed  
  30. Moriarty LF, Plucinski MM, Marston BJ, et al. Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020. MMWR Morb Mortal Wkly Rep 2020;69:347-352. DOI: http://dx.doi.org/10.15585/mmwr.mm6912e3external icon
  31. Liu Y, Yan LM, Wan L. Viral dynamics in mild and severe cases of COVID-19. The Lancet Infectious Diseases. Published: March 19, 2020 DOI:https://doi.org/10.1016/S1473-3099(20)30232-2
  32. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19 published online ahead of print, 2020 Apr 9. Clin Infect Dis. 2020;ciaa351. doi:10.1093/cid/ciaa351 PMID: 32271376 PubMed  
  33. Li J, Zhang L, Liu B, Song D. Case Report: Viral Shedding for 60 Days in a Woman with Novel Coronavirus Disease (COVID-19) published online ahead of print, 2020 Apr 27. Am J Trop Med Hyg. 2020;10.4269/ajtmh.20-0275. PMID: 32342849. PubMed  
  34. Yang JR, Deng DT, Wu N, Yang B, Li H, Pan X. Persistent viral RNA positivity during recovery period of a patient with SARS‐CoV‐2 infection. J Med Virol. 2020:jmv.25940.
  35. He X, Lau EHY, Wu P et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med (2020). https://doi.org/10.1038/s41591-020-0869-5
  36. Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized patients with COVID-2019. Nature (2020). https://doi.org/10.1038/s41586-020-2196-x
  37. Cheng H, Jian S, Liu D, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. JAMA Intern Med. Published online May 01, 2020. doi:10.1001/jamainternmed.2020.2020 DOI  
  38. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. PMID: 32661059 2020;369(6504):718-24.
  39. Chiang CC, Korinek M, Cheng WJ, et al. Targeting neutrophils to treat acute respiratory distress syndrome in coronavirus disease. Front Pharmacol. PMID: 33162887 2020;11:572009.
  40. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. PMID: 32073213 2020;18(4):844-7
  41. Chen W, Pan JY. Anatomical and pathological observation and analysis of SARS and COVID-19: microthrombosis is the main cause of death. Biol Proced Online. PMID: 33472576 2021;23(1):4.
  42. Bastard P, Rosen L, Zhang Q et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science 24 Sep 2020. eabd4585. DOI: 10.1126/science.abd4585 DOI  
  43. Zhang Q, Bastard P, Liu Z et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 24 Sep 2020: eabd4570. DOI: 10.1126/science.abd4570 DOI  
  44. Combes AJ, Courau T, Kuhn NF. Global absence and targeting of protective immune states in severe COVID-19. Published online: 25 January 2021. https://doi.org/10.1038/s41586-021-03234-7
  45. Hellman U, Karlsson MG, Enström-Laurent A et al. Presence of hyaluronan in lung alveoli in severe Covid-19 - an opening for new treatment options? Journal of Biological Chemistry. September 25, 2020. jbc.AC120.015967. doi: 10.1074/jbc.AC120.015967 DOI  
  46. Folkhälsomyndigheten. Frågor och svar om covid-19. Hämtad 2020-03-18 www.folkhalsomyndigheten.se  
  47. Sekine T, Perez-Potti A, Rivera-Ballestenos. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell, online. DOI:https://doi.org/10.1016/j.cell.2020.08.017
  48. Bogetofte Barnkob M, Pottegård A, Støvring H. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. Blood Adv 2020; 4 (20): 4990–4993. doi: https://doi.org/10.1182/bloodadvances.2020002657
  49. Hoiland RL, Fergusson NA, Mitra RA et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv 2020; 4 (20): 4981–4989. doi: https://doi.org/10.1182/bloodadvances.2020002623
  50. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients published online ahead of print, 2020 Feb 27. J Med Virol. 2020;10.1002/jmv.25728. PMID: 32104915. PubMed  
  51. Edén A, Kanberg N, Gostner J et al. CSF biomarkers in patients with COVID-19 and neurological symptoms. A case series.Neurology Oct 2020, 10.1212/WNL.0000000000010977; DOI: 10.1212/WNL.0000000000010977 DOI  
  52. Virhammar, J., Nääs, A., Fällmar, D., Cunningham, J. L., Klang, A., Ashton, N. J., … Rostami, E. (2020). Biomarkers for CNS injury in CSF are elevated in COVID-19 and associated with neurological symptoms and disease severity. <i>European Journal of Neurology</i>. Epub ahead of print. https://doi.org/10.1111/ene.14703
  53. Liu JM, Tan BH, Wu S et al. Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS-CoV-2 infection. J Med Virol. 2021 Mar;93(3):1304-1313. doi: 10.1002/jmv.26570. Epub 2020 Oct 14. PMID: 33002209; PMCID: PMC7537172.
  54. Lie T, Dahl Å. Kan höga pollenhalter bidra till allvarligare fall av covid-19? Debattartikel Läkartidningen. 2020-03-26. Hämtad 2020-03-31. lakartidningen.se  
  55. Damialis A, Gilles S, Sofiev M et al. Higher airborne pollen concentrations correlated with increased SARS-CoV-2 infection rates, as evidenced from 31 countries across the globe. PNAS March 23, 2021 118 (12) e2019034118; https://doi.org/10.1073/pnas.2019034118
  56. Socialstyrelsen. Riskgrupper. Publicerad: 2021-03-22 www.socialstyrelsen.se  
  57. Bergman J, Ballin M, Nordström A, Nordström P. Risk factors for COVID-19 diagnosis, hospitalization and subsequent all-cause mortality in Sweden: a nationwide studyEuropean Journal of Epidemiology. DOI: 10.1007/s10654-021-00732-w DOI  
  58. Socialstyrelsen. Identifiering av riskgrupper som löper störst risk att drabbas av ett särskilt allvarligt sjukdomsförlopp vid insjuknande i covid-19. Dnr 5.7-13632/2020. 2020-04-17. Hämtad 2020-04-22. www.socialstyrelsen.se  
  59. Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children. JAMA Netw Open. 2021;4(6):e2111182. doi:10.1001/jamanetworkopen.2021.11182 DOI  
  60. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775 DOI  
  61. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China.Allergy. 2020; (published online Feb 19.)DOI:10.1111/all.14238 DOI  
  62. Yang X, Yu Y, Xu J.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.Lancet Respir Med. 2020; (published online Feb 24)https://doi.org/10.1016/S2213-2600(20)30079-5 www.thelancet.com  
  63. Wambier CG, Vano-Galván S, McCoy J. Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign”. Journal of the American Academy of DermatologyAvailable online 22 May 2020 doi:https://doi.org/10.1016/j.jaad.2020.05.079
  64. Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol 2020 (pre-print posted online July 7, 2020) gi.org  
  65. Folkhälsomyndigheten. Förekomst av covid-19 i olika yrkesgrupper. Bekräftade covid-19 fall i Sverige 13 mars - 27 maj 2020. Artikelnummer: 20099. medibas.se  
  66. Svenska Infektionsläkarföreningen, Svenska Hygienläkarföreningen och Föreningen för Klinisk Mikrobiologi. Nationellt vårdprogram för misstänkt ochbekräftad covid-19. Version 1.2 september 2020.
  67. Svenska infektionsläkarföreningen. Nationellt vårdprogram covid-19. Version 3.4, December 2021. Hämtat 2022-02-27. infektion.net  
  68. Garg S, Kim L, Whitaker M et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14. CDC MMWR Early Release. April 17, 2020 69(15);458–464 States, March 1–30, 2020 www.cdc.gov  
  69. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients published online ahead of print, 2020 Mar 27. J Infect. 2020;. PMID: 32171866 PubMed  
  70. Niu S, Tian S, Lou J, et al. Clinical characteristics of older patients infected with COVID-19: A descriptive study published online ahead of print, 2020 Apr 10. Arch Gerontol Geriatr. 2020;89:104058. PubMed  
  71. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. Ann Intern Med. 2021 May;174(5):655-662. 2021 Jan 22. PMID: 33481642;
  72. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. Published 2020 Sep 1. PMID: 32873575 PubMed  
  73. Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics 2020;16:16. doi: https://dx.doi.org/10.1542/peds.2020-0702
  74. The Australasian College of Dermatologists. Skin signs of COVID-19. Publicerade 2020-04-30. Hämtad 20-05-28. www.dermcoll.edu.au  
  75. Emcrit: Internet Book of Critical Care (IBCC). 2020-03-02. Hämtad 2020-03-24. emcrit.org  
  76. The Centre for Evidence-Based Medicine. What is the efficacy and safety of rapid exercise tests for exertional desaturation in covid-19? April 21, 2020. Hämtad 2020-05-07. www.cebm.net  
  77. Greenhalgh T, Koh G, Car J. Covid-19: a remote assessment in primary care. BMJ 2020;368:m1182. doi: https://doi.org/10.1136/bmj.m1182
  78. Folkhälsomyndigheten. Stanna hemma om du är sjuk med symtom på covid-19. Hämtad 2022-02-27. www.folkhalsomyndigheten.se  
  79. Folkhälsomyndigheten. Rekommendationer för handläggning och val av skyddsåtgärder mot covid-19 inom vård och omsorg. Publicerad 30 mars 2020. Hämtad 2020-03-31. www.folkhalsomyndigheten.se  
  80. Folkhälsomyndigheten. Uppdaterade rekommendationer för PCR-provtagning av pågående infektion i covid-19. Publicerad 2020-10-16. Hämtad 2020-10-26. www.folkhalsomyndigheten.se  
  81. Folkhälsomyndigheten. Vägledning för användning av antigentester vid covid-19. Version 4, 2021-05-12. Hämtad 2021-06-16.
  82. Läkemedelsverket. Nyheter: Hemmatester för covid-19 är inte tillförlitliga. Publicerat 21 april 2020. Hämtat 2020-04-27.
  83. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. Published online February 7, 2020. jamanetwork.com  
  84. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19, JTH March 2020 dot:10.1111/JTH.14810
  85. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. Epub 17 mar 2020. doi: 10.1001/jama.2020.4344. DOI  
  86. Zhang J, Zhou L, Yang Y, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8(3):e11–e12. PMID:32061335. PubMed  
  87. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. PMID:32029004. PubMed  
  88. Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adultinpatients with COVID-19 in Wuhan, China: a retrospectivecohort study. The Lancet. Published online. March 9, 2020. PMID: 32171076 PubMed  
  89. Janusinfo, Hulting J, Askelöf S, Söderberg M. Covid-19-infektion. Publicerat 2020-04-22. Hämtat 2020-04-27. janusinfo.se  
  90. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Published online March 27, 2020. doi:10.1001/jamacardio.2020.1017 DOI  
  91. Hägg S, Jylhävä J, Wang Y et al. Age, frailty and comorbidity as prognostic factors for short-term outcomes in patientswith COVID-19 in geriatric care. JMDA 3605. 14 aug 2020. https://doi.org/10.1016/j.jamda.2020.08.014
  92. Ai T, Yang Z, Hou H et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. Published Online:Feb 26 2020.
  93. Inui S, Fujikawa A, Jitsu M et al. Radiology: Cardiothoracic imaging. Chest CT Findings in Cases from the Cruise Ship “Diamond Princess” with Coronavirus Disease 2019 (COVID-19) pubs.rsna.org  
  94. Folkhälsomyndigheten. Diagnostik av coronavirus 2019-nCoV, ett nytt virus som orsakat ett utbrott av allvarlig lunginflammation i Kina. Hämtad 2020-01-29.
  95. Folkhälsomyndigheten. Vägledning för antikroppspåvisning. Version 6, 2021-02-25. Artikelnummer: 21043. Hämtad: 2021-03-09. www.folkhalsomyndigheten.se  
  96. Mo H, Zeng G, Ren X, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology. 2006;11(1):49-53. PubMed  
  97. Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562-4. PubMed  
  98. Callow KA, Parry HF, Sergeant M, et al. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105 (2):435-46.
  99. Payne DC, Iblan I, Rha B, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824-6. PubMed  
  100. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 published online ahead of print, 2020 Mar 28. Clin Infect Dis. 2020;ciaa344. PMID: 32221519. PubMed  
  101. ESTUDIO ENE-COVID19: PRIMERA RONDA ESTUDIO NACIONAL DE SERO-EPIDEMIOLOGÍA DE LA INFECCIÓN POR SARS-COV-2 EN ESPAÑA INFORME PRELIMINAR 13 DE MAYO DE 2020 medibas.se  
  102. Steensels D, Oris E, Coninx L, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. JAMA. Published online June 15, 2020. doi:10.1001/jama.2020.11160 DOI  
  103. Ward H, Atchison C, Whitaker M. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. PREPRINT.
  104. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland published online ahead of print, 2020 Sep 1. N Engl J Med. 2020;NEJMoa2026116. PMID: 32871063 PubMed  
  105. Referensgruppen för AntiViral terapi (RAV), Svenska Läkaresällskapet. Behandling av COVID-19 infektion Version 2020-03-22. Hämtad 2020-03-26 www.sls.se  
  106. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. Published online March 27, 2020. doi:10.1001/jama.2020.4783 DOI  
  107. Läkartidningen. Astra Zenecas covidläkemedel för riskgrupper får licens i Sverige. Lakartidningen.se 2022-03-23. cms.medibas.se  
  108. Läkemedelsverket. EMA rekommenderar Roactemra hos vuxna med svår covid‍-‍19. Publicerad 2021-12-08. Hämtad 2021-12-25. www.lakemedelsverket.se  
  109. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. N Engl J Med. Epub 25 feb 2021. doi: 10.1056/NEJMoa2028700.
  110. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with covid-19 pneumonia. N Engl J Med. 2021;384(1):20-30. PubMed  
  111. Stone JH, Frigault MJ, Serling-Boyd NJ, et al; BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020;383(24):2333-44. PubMed  
  112. Blennow O, Vesterbacka J, Nowak P. Tocilizumab bör övervägas i tidigt skede av svår covid-19. Läkartidningen. 2021;118:21047 medibas.se  
  113. WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. Publicerad 2020-10-15. www.medrxiv.org  
  114. Läkemedelsverket. Remdesivir – den första behandlingen av covid-19 som EMA rekommenderar för godkännande. Nyheter. Publicerad 2020-06-25. Hämtad 2020-06-29. www.lakemedelsverket.se  
  115. Mehra MR, Desai SS, Ruschitzka F. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. Published May 22, 2020.
  116. Barbosa J, Kaitis D, Freedman R et al. Clinical outcomes of hydroxychloroquine in hospitalized patients with covid-19: A Quasi-randomized comparative study. The New England Journal of Medicine (NEJM). 04 apr 2020.
  117. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 published online ahead of print, 2020 Mar 10. J Crit Care. 2020;S0883-9441(20)30390-7. doi:10.1016/j.jcrc.2020.03.005 DOI  
  118. Malgie J, Schoones JW, Pijls BG. Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis. 2020 Sep 23:ciaa1445. doi: 10.1093/cid/ciaa1445. Epub ahead of print. PMID: 32964913;
  119. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.. N Engl J Med 2020; Epub: Mar 18. pmid:32187464 PubMed  
  120. Chen L, Xiong J, Bar L. Convalescent plasma as a potential therapy for COVID-19. 20(4) P398-400, april 01, 2020 DOI:https://doi.org/10.1016/S1473-3099(20)30141-9.
  121. Duan K, Liu B, Zhang H, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS 2020. https://doi.org/10.1073/pnas.2004168117
  122. Regeneron press release. REGENERON'S REGN-COV2 ANTIBODY COCKTAIL REDUCED VIRAL LEVELS AND IMPROVED SYMPTOMS IN NON-HOSPITALIZED COVID-19 PATIENTS. Publicerad 2020-09-29. Hämtad 2020-10-20.
  123. Läkemedelsverket. EMA avråder från användning av ivermektin mot covid‍-‍19. Publicerad 2021-03-24. Hämtad 2021-04-08.
  124. Svenska Infektionsläkarföreningen, Svenska Hygienläkarföreningen och Föreningen för Klinisk Mikrobiologi. Nationellt vårdprogram för misstänkt och bekräftad covid-19. Version 1.0 juni 2020. Hämtad 2020-07-10. infektion.net  
  125. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. July 17, 2020. DOI: 10.1056/NEJMoa2021436 DOI  
  126. Läkemedelsverket. EMA utvärderar dexametason för behandling av vuxna med covid-19. Publicerad: 29 juli 2020. Hämtad 2020-08-12.
  127. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. Published online September 02, 2020. doi:10.1001/jama.2020.17023 DOI  
  128. Russell CD, Millar JE, Baillie KJ. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. 395(10223) 473-475, 2020 doi.org  
  129. Shang L, Zhao J, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. 395(10225) 638-684, 2020 doi.org  
  130. Heneghan C, Aronson J, Hobbs R et al. Rapidly managing pneumonia in older people during a pandemic. The Centre for Evidence-Based Medicine (CEBM). Hämtad 2020-03-25 www.cebm.net  
  131. FAQ till koagulationskonsult. Karolinska Sjukhuset. Uppdaterad 2020-04-29. Hämtad 2020-06-15. www.karolinska.se  
  132. Janusinfo, Region Stockholms läkemedelskommittés expertgrupp för äldres hälsa. Trombosprofylax vid covid-19 på SÄBO. Publicerat 2020-04-27. Hämtad 2020-04-27.
  133. Janusinfo, Region Stockholms läkemedelskommittés expertgrupp för koagulationssjukdomar och plasmaprodukter. Publicerad 2020-04-17, uppdaterad 2020-04-23. Riktlinjer för profylax och behandling av venös tromboembolism hos patienter med covid-19. Hämtad 2020-04-27. janusinfo.se  
  134. Helms J, Tacquard C, Severac F et al. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Medicine (2020); DOI: 10.1007/s00134-020-06062-x DOI  
  135. Ackermann M, Verleden SE, Kuehnel M. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. The New England Journal of Medicine. May 21, 2020. DOI: 10.1056/NEJMoa2015432 DOI  
  136. Paranjpe I, Fuster V, Lala A. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. J Am Coll Cardiol. 2020 May 06. Epublished DOI:10.1016/j.jacc.2020.05.001 DOI  
  137. Tang N, Bai H, Chen X et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
  138. Pesavento R, Ceccato D, Pasquetto G, et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience published online ahead of print, 2020 Jul 21. J Thromb Haemost. 2020;10.1111/jth.15022. doi:10.1111/jth.15022 PMID: 32692874 PubMed  
  139. The Centre for Evidence-Based Medicine (CEBM). Vitamin D: A rapid review of the evidence for treatment or prevention in COVID-19. May 1 2020. Hämtad 2020-05-18. www.cebm.net  
  140. Fowler AA, Truwit JD, Hite RD, et al. Effect of vitamin C infusion on organfailure and biomarkers of inflammation and vascular injury in patients withsepsis and severe acute respiratory failure: the CITRIS-ALI randomizedclinical trial. JAMA 2019; 322: 1261–70.
  141. Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?. Med Drug Discov. 2020;5:100028. doi:10.1016/j.medidd.2020.100028 DOI  
  142. Moskowitz A, Huang DT, Hou PC, et al. Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial. JAMA. 2020;324(7):642–650. doi:10.1001/jama.2020.11946 DOI  
  143. Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care. 2020;24(1):133. Published 2020 Apr 7. doi:10.1186/s13054-020-02851-4. PMID: 322649623 PubMed  
  144. Svensk Reumatologisk Förening. Vägledning för vårdpersonal och patienter med reumatologisk sjukdom angående utbrott av COVID-19. Hämtad 2020-03-19 svenskreumatologi.se  
  145. American College of Rheumatology, Frequently Asked Questions. Hämtad 2020-03-19. www.rheumatology.org  
  146. European Society of Cardiology, Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers, 13 Mar 2020 Hämtad 2020-03-17 www.escardio.org  
  147. Mehra MR, Desai SS, Kuy SR. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. The New England Journal of Medicine (NEJM). May 1, 2020. DOI: 10.1056/NEJMoa2007621 DOI  
  148. European Medicines Agency (EMA). Press release: "EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic" 2020-03-27. hämtad 2020-04-01. www.ema.europa.eu  
  149. Kow CS, Hasan SS. Meta-analysis of Effect of Statins in Patients with COVID-19. The American Journal of Cardiology. Published online: August 11, 2020. https://doi.org/10.1016/j.amjcard.2020.08.004
  150. Region Stockholms läkemedelskommittés expertgrupp för lung- och allergisjukdomar i samarbete med Akademiskt Primärvårdscentrum. Undvik nebulisator inom sjukvården med anledning av covid-19. Publicerat 2020-04-08. Hämtad 2020-05-06.
  151. American Thoracic Society. Diagnosis and Management of COVID-19 Disease. Am J Respir Crit Care Med 2020. doin:10.1164/rccm.2020C1 www.atsjournals.org  
  152. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Ramakrishnan S, Nicolau D, Langford B et al. Published:April 09, 2021DOI:https://doi.org/10.1016/S2213-2600(21)00160-0
  153. Walker A, Pottinger G, Scott A, Hopkins C. Anosmia and loss of smell in the era of covid-19 BMJ 2020; 370 :m2808 doi: https://doi.org/10.1136/bmj.m2808
  154. Svenska Infektionsläkarföreningen. Uppdatering om COVID-19. Videomöte, upptaget är öppet för allmänheten. 21:a mars 2020. infektion.net  
  155. https://www.karolinska.se/for-patienter/alla-behandlingar-och-undersokningar-a-o/anopiva-solna/HBOT/
  156. Thibodeaux K, Speyrer M, Raza A, Yaakov R, Serena TE. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care. 2020;29(Sup5a):S4‐S8. PMID: 32412891. PubMed  
  157. Socialstyrelsen. Nytt stöd för att möta ökat behov av rehabilitering efter covid-19. Pressmeddelande 2020-05-15. www.socialstyrelsen.se  
  158. Socialstyrlesen. Rehabilitering i samband med covid-19 i primärvården Praktiskt kunskapsstöd till vård- och omsorgspersonal i regioner och kommuner. 2020-05-15. medibas.se  
  159. Chu DK, Aki E, Duda S. MScPhysical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. The Lancet. Published:June 01, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31142-9
  160. Jones Nicholas R, Qureshi Zeshan U, Temple Robert J, Larwood Jessica P J, Greenhalgh Trisha, Bourouiba Lydia et al. Two metres or one: what is the evidence for physical distancing in covid-19? BMJ 2020; 370 :m3223
  161. Clase CM, Fu EL, Ashur A et al. Forgotten Technology in the COVID-19 Pandemic. Filtration Properties of Cloth andCloth Masks: A Narrative Review. Mayo Clinic Proceedings 2020. DOI: https://doi.org/10.1016/j.mayocp.2020.07.020
  162. Chen YJ, Qin G, Chen J et al. Comparison of Face-Touching Behaviors Before and During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020;3(7):e2016924. doi:10.1001/jamanetworkopen.2020.16924 DOI  
  163. Bae S, Kim M, Kim JY, et al. Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients. Ann Intern Med. 2020; Epub ahead of print 6 April 2020. doi: https://doi.org/10.7326/M20-1342
  164. Nussbaumer‐Streit B, Mayr V, Dobrescu AI. Quarantine alone or in combination with other public health measures to control COVID‐19: a rapid review. Cochrane Database of Systematic Reviews 2020, Issue 4. Art. No.: CD013574. DOI: 10.1002/14651858.CD013574. DOI  
  165. Folkhälsomyndigheten. Frågor och svar om covid-19. "hur länge ska jag stanna hemma?". Publicerad 2020-06-10, Hämtad 2020-06-11
  166. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD000980. DOI: 10.1002/14651858.CD000980.pub4 DOI  
  167. Hemilä H, Louhiala P. Vitamin C for preventing and treating pneumonia. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD005532. DOI: 10.1002/14651858.CD005532.pub3 DOI  
  168. Flam B, Pasternak B. Pågående NOAK-användning tycks inte skydda mot svår covid-19. Läkartidningen 49-50/2020 lakartidningen.se  
  169. Palliativt kunskapscentrum. Palliativ symtomlindring vid covid-19 i allmän palliativ vård (ny version 2020-03-30). Hämtad 2020-04-08. www.pkc.sll.se  
  170. Hedman C, Bergström J, Fürst P. Stockholms Sjukhem: Palliativ vård. Version 2020-03-26 www.nrpv.se  
  171. Rekommendationer för hantering av avliden med bekräftad covid-19. Folkhälsomyndigheten. 2020-03-17. Hämtad 2020-03-27. www.folkhalsomyndigheten.se  
  172. Läkemedelsverket. Rapportera alla misstänkta biverkningar med koppling till covid-19. Nyheter. Publicerad: 24 april 2020. Hämtad 2020-04-27. www.lakemedelsverket.se  
  173. Försäkringskassan. Coronaviruset – det här gäller. Publicerad och hämtad 2020-10-26. www.forsakringskassan.se  
  174. Lakartidningen. Gravida ska inte arbeta med covid-19-patienter. 2020-09-18 lakartidningen.se  
  175. Walter K. COVID-19 and Pregnancy. JAMA. 2022;327(8):790. doi:10.1001/jama.2021.22679 DOI  
  176. Folkhälsomyndigheten. Gravida med riskfaktorer rekommenderas att vara extra försiktiga. Nyhet publicerad 2020-04-29. Hämtad 2020-04-29.
  177. Intensive Care National Audit and Research Centre. ICNARC report on COVID-19 in critical care. Case Mix Programme Database. 20 March 2020 www.icnarc.org  
  178. Folkhälsomyndigheten. Vägledning om kriterier för bedömning av smittfrihet vid covid-19. Hämtad 2020-05-27. www.folkhalsomyndigheten.se  
  179. Al-Aly Z, Xie Y and Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature (2021). https://doi.org/10.1038/s41586-021-03553-9. PMID: 33887749. PubMed  
  180. Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021 Aug 14;398(10300):599-607. doi: 10.1016/S0140-6736(21)00896-5. Epub 2021 Jul 29. PMID: 34332652; PMCID: PMC8321431.
  181. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. Epub 3 mar 2020. doi: 10.1007/s00134-020-05991-x. DOI  
  182. Ahlberg M, Neovius M, Saltvedt S, et al. Association of SARS-CoV-2 Test Status and Pregnancy Outcomes. JAMA. Published online September 23, 2020. doi:10.1001/jama.2020.19124 DOI  
  183. Helms J, Kremer S, Merdji H. Neurologic Features in Severe SARS-CoV-2 Infection. Correspondance, The New England Journal of Medicine. April 15, 2020. DOI: 10.1056/NEJMc2008597 DOI  
  184. Sjögren L, Stenberg E, Thuccani M et al. Impact of obesity on intensive care outcomes in patients with COVID-19 in Sweden—A cohort study. Published: October 13, 2021https://doi.org/10.1371/journal.pone.0257891
  185. Folkhälsomyndigheten, Information till riskgrupper om covid-19. Uppdaterat: 2020-07-02. Hämtad 2020-07-10. www.folkhalsomyndigheten.se  
  186. L Huang, Q Yao, X Gu. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Volume 398, Issue 10302, P747-758. AUGUST 28, 2021. DOI:https://doi.org/10.1016/S0140-6736(21)01755-4
  187. Cederberg J. Högsta dödstalet denna sida millennieskiftet. Läkartidningen, nyhet. Publicerad 2020-04-27. Hämtad 2020-04-29. lakartidningen.se  
  188. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. Published online March 23, 2020. doi:10.1001/jama.2020.4683 DOI  
  189. Yin S, Huang M, Li DDifference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis (2020). https://doi.org/10.1007/s11239-020-02105-8
  190. Cariou B, Hadjadj S, Wargny M et al.. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.. Diabetologica 2020. pmid:doi.org/10.1007/s00125-020-05180-x
  191. COVID-19 Surveillance Group, Italy. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020
  192. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team . The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly 2020; 2: 113-121. weekly.chinacdc.cn  
  193. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 February 2020 (Hämtad 2020-03-03). www.who.int  
  194. Arentz M, Yim E, Klaff L et al. Research letter: Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. Published online March 19, 2020. doi:10.1001/jama.2020.4326 jamanetwork.com  
  195. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 16-24 February 2020. www.who.int  
  196. Zhou P, Huang Z, Xiao Y, Huang X, Fan X-G. Protecting Chinese Healthcare Workers While Combating the 2019 Novel Coronavirus. Infection Control & Hospital Epidemiology.:1-4. doi:10.1017/ice.2020.60 DOI  
  197. FNOMCeO Portale della Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri. Elenco dei Medici caduti nel corso dell’epidemia di Covid-19. Hämtad 2020-04-09- portale.fnomceo.it  
  198. WHO: DEPARTMENT OF COMMUNICABLE DISEASE SURVEILLANCE AND RESPONSE. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). 2013. Hämtad 2020-03-20. www.who.int  
  199. Svensk Gastroenterologisk Förening. Råd till vårdgivare för patienter med leversjukdomar under COVID-19 pandemi. Leversjukdom och COVID-19 (2020-03-23).
  200. Svensk Gastroenterologisk Förening. Råd till vårdgivare för patienter med IBD (Inflammatory Bowel Disease) under COVID-19 pandemin. Publicerat 2020-03-26. Hämtat 2020-03-26.
  201. Folkhälsomyndigheten. Vägledning för bedömning av immunitet efter infektion med covid-19. 2020-07-21 (Hämtad 2020-07-21). www.folkhalsomyndigheten.se  
  202. Thålin C, Havervall S, Schmitz B. Pressmeddelande angående COMMUNITY-studien; Bred immunitet mot covid-19 efter 9 månader. www.ds.se  
  203. Läkartidningen. Studie: Antikroppar kvar ett år efter lindrig covid. Lakartidningen.se 2021-07-15. Hämtad 2021-09-10. lakartidningen.se  
  204. Wajnberg A, Amanat F, Firpo A. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.Science Vol. 370, Issue 6521, pp. 1227-1230DOI: 10.1126/science.abd7728 DOI  
  205. CDC, Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. Weekly / July 31, 2020 / 69(30);993-998
  206. Carfì A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA 2020. doi:10.1001/jama.2020.12603 DOI  
  207. Klironomos S, Tzortzakakis A, Kits A. Nervous System Involvement in COVID-19: Results from a Retrospective Consecutive Neuroimaging Cohort. Published Online:Jul 30 2020 https://doi.org/10.1148/radiol.2020202791
  208. Lokken EM, Huebner EM, Taylor G et al. Disease Severity, Pregnancy Outcomes and Maternal Deaths among Pregnant Patients with SARS-CoV-2 Infection in Washington State. American Journal of Obstetrics and Gynecology. Published December 2020. https://doi.org/10.1016/j.ajog.2020.12.1221
  209. Socialstyrelsen. Halvering av andelen döda bland dem som sjukhusvårdats för covid-19. Publicerad: 2020-11-24. Hämtad 2020-02-18. www.socialstyrelsen.se  
  210. Socialstyrelsen. Statistik om smittade och avlidna med covid-19 bland äldre efter boendeform. Dnr. 6.7-15552/2020 1. 2020-05-06. medibas.se  
  211. Folkhälsomyndigheten. Skattning av letaliteten för covid-19 i Stockholms län. Artikelnummer: 20094-1. Reviderad 20-06-17. www.folkhalsomyndigheten.se  
  212. Drefahl S, Wallace M, Mussino E, et al. Socio-demographic risk factors of COVID-19 deaths in Sweden: A nationwide register study. June 2020. doi:10.17045/sthlmuni.12420347.v3 DOI  
  213. Allotey J, Stallings E, Bonet M. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3320
  214. Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease published online ahead of print, 2020 Feb 28. Chin Med J (Engl). 2020;10.1097/CM9.0000000000000775. doi:10.1097/CM9.0000000000000775 DOI  
  215. Janusinfo, Region Stockholms läkemedelskommittés expertgrupp för äldres hälsa. Kortisonbehandling vid covid-19 på SÄBO. Publicerat 2020-07-20. Hämtad 2020-08-12.
  216. Inga nya rekommendationer från Läkemedelsverket angående febernedsättande läkemedel vid covid-19. Nyheter Läkemedelsverket. Hämtad 2020-03-19 www.lakemedelsverket.se  
  217. European Medicines Agency EMA. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. Press release 18/03/2020. Hämtad 2020-03-25 www.ema.europa.eu  
  218. World Health Organization, WHO. Twitter account, official. Hämtad 2020-03-19 [url]https://twitter.com/WHO/status/1240409217997189128?
  219. Svensk Förening för Anestesi och Intensivvård (SFAI). Farmakologisk behandling av patienter med lunginflammation i samband med COVID-19. Hämtad 2020-04-23. medibas.se  
  220. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. PubMed  
  221. Beigel JH, Tomashek K, Dodd LE et al. Remdesivir for the Treatment of Covid-19 — Final Report. October 8, 2020 DOI: 10.1056/NEJMoa2007764 medibas.se  
  222. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial published online ahead of print, 2020 Apr 29. Lancet. 2020;doi:10.1016/S0140-6736(20)31022-9 DOI  
  223. Goldman JD, Lye DCB, Hui DS, et al.; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May 27. doi: 10.1056/NEJMoa2015301. Epub ahead of print. PMID: 32459919. PubMed  
  224. Burch J, Bunt C. Can physical interventions help reduce the spread of respiratory viruses? Cochrane Clinical Answers. 2020DOI: 10.1002/cca.2965 DOI  
  225. Svensk Förening för Medicinsk Radiologi (SFMR) och Svensk Förening för Thoraxradiologi. Radiologiska rekommendationer vid Covid-19-infektion. Uppdaterad 2020-03-19, hämtad 2020-03-24 www.sfmr.se  
  226. Lindahl JF, Hoffman T, Esmaeilzadeh M. High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden. Infection Ecology & Epidemiology 10(1) 2020. https://doi.org/10.1080/20008686.2020.1789036
  227. World Health Organozation. Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts. Interim guidance, 17March 2020.
  228. Kucirka LM, Lauer SA, Laeyendecker O et al. False-Negative Rate of RT-PCR SARS-CoV-2 Tests. American College of Cardiology. May 18 2020. www.acc.org  
  229. Folkhälsomyndigheten.Provtagningsindikation för nukleinsyrapåvisning vid covid-19, version 14. 2020-06-17. www.folkhalsomyndigheten.se  
  230. Folkhälsomyndigheten. Vägledning för smittspårning av covid-19. Hämtad 2020-03-09.
  231. Folkhälsomyndigheten. Uppdaterade rekommendationer om testning. Nyheter. Publicerad 2021-11-14. Hämtad 2021-11-19. www.folkhalsomyndigheten.se  
  232. Folkhälsomyndigheten. Provtagning för covid-19 inom kommunal vård och omsorg för äldre. Artikelnummer: 20078-2. Utgivningsdatum: 2020-06-17. www.folkhalsomyndigheten.se  
  233. Arons MM, Hatfield KM, Reddy SC et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. April 24, 2020. The New England Journal of Medicine. medibas.se  
  234. Pan L, Mu M, Yang P et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study, The American Journal of Gastroenterology. Hämtad 2020-03-25 journals.lww.com  
  235. Beltrán‐Corbellini A, Chico‐García JL, Martínez‐Poles J. Acute‐onset smell and taste disorders in the context of Covid‐19: a pilot multicenter PCR‐based case‐control study. 22 April 2020. European Journal of Neurology. https://doi.org/10.1111/ene.14273
  236. Lundström JN, Stjärne P. Förlorat luktsinne – möjligt tidigt tecken på covid-19. Läkartidningen. 2020;117:F3P9. lakartidningen.se  
  237. Lüers JC, Klußmann JP, Guntinas-Lichius O. Die Covid-19-Pandemie und das HNO-Fachgebiet: Worauf kommt es aktuell an? The Covid-19 pandemic and otolaryngology: What it comes down to? published online ahead of print, 2020 Mar 26. Laryngorhinootologie. 2020;10.1055/a-1095-2344. PMID: 32215896. PubMed  
  238. Scangas GA, Bleier BS. Anosmia: Differential Diagnosis, Evaluation, and Management. American Journal of Rhinology & Allergy, 31(1), e3–e7. (2017) doi:10.2500/ajra.2017.31.4403 DOI  
  239. Barnreumatologiska föreningen. Riktlinjer för tidig upptäckt, utredning och omhändertagande av barn med hyperinflammation associerad till COVID-19. Publicerad 2020-06-12. Hämtad 2020-10-27. medibas.se  
  240. Riphagen S, Gomez X, Gonzalez-Martinez C et al.. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet, Correspondence 2020. doi:doi.org/10.1016/S0140-6736(20)31094-1
  241. Verdoni L, Mazzo A, Gervasoni A. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet, May 13, 2020. https://doi.org/10.1016/S0140-6736(20)31103-X
  242. Consiglio CR, Cotugno N, Sardh F. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. September 06, 2020 DOI:https://doi.org/10.1016/j.cell.2020.09.016
  243. Suwanwongse K, Shabarek N. Rhabdomyolysis as a Presentation of 2019 Novel Coronavirus Disease. Cureus. 12(4): e7561. DOI 10.7759/cureus.7561
  244. WHO. Q&A on coronaviruses (COVID-19). (Hämtad 2020-03-10). www.who.int  
  245. Tilett RL, Sevinsky JR, Hartley P. Genomic evidence for reinfection with SARS-CoV-2: a case study. THe Lancet Infectious Diseases. Online First. Published:October 12, 2020 DOI:https://doi.org/10.1016/S1473-3099(20)30764-7
  246. Davies NG, Abbott S, Barnard R et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 03 Mar 2021: eabg3055 DOI: 10.1126/science.abg3055 DOI  
  247. Struyf T, Deeks JJ, Dinnes J et al. Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD013665. doi: 10.1002/14651858.CD013665. PMID: 32633856; PMCID: PMC7386785 The Cochrane Library  
  248. Smith V, Seo D, Warty R, et al. Maternal and neonatal outcomes associated with COVID-19 infection: A systematic review. PLoS One. 2020;15(6):e0234187. Published 2020 Jun 4. doi:10.1371/journal.pone.0234187 DOI  
  249. SBU. Covid-19 vid graviditet Internet. Stockholm: Statens beredning för medicinsk och social utvärdering (SBU); 2021. SBU:s upplysningstjänst. 2021-05-25. Available from: https://www.sbu.se/ut202105
  250. Liu D, Lin L, Wu X. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. American Journal of Roentgenology: 1-6. 10.2214/AJR.20.23072
  251. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020. doi:10.1016/S0140-6736(20)30360-3 DOI  
  252. Läkemedelsverket. EMA rekommenderar monoklonala antikropps­läkemedel mot covid‍-‍19. Publicerad: 15 november 2021. Senast uppdaterad: 15 november 2021. www.lakemedelsverket.se  
  253. Lu Y, Li Y, Deng W, et al. Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan published online ahead of print, 2020 May 5. Pediatr Infect Dis J. 2020;10.1097/INF.0000000000002729. PMID: 32379191 PubMed  
  254. Park YJ, Choe YJ, Park O, Park SY, Kim YM, Kim J, et al. Contact tracing during coronavirus disease outbreak, South Korea, 2020. Emerg Infect Dis. 2020 Oct. DOI:10.3201/eid2610.201315. DOI  
  255. Hu X, Xing Y, Jia J, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19 published online ahead of print, 2020 Apr 22. Sci Total Environ. 2020;728:138812. PMID: 32335406 PubMed  
  256. Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front. Immunol., 01 May 2020https://doi.org/10.3389/fimmu.2020.00827 T-cellsaktivitet, CD4 kopplat till outcome.
  257. Läkemedelsverket. Beredskapslicens beviljad med anledning av covid-19. Nyheter 2020-03-11 www.lakemedelsverket.se  
  258. Läkemedelsverket. EMA rekommenderar nytt covidläkemedel. Publicerad 2021-03-08. Hämtad 2021-04-03. www.lakemedelsverket.se  
  259. Folkhälsomyndigheten. Nya allmänna råd: Håll avstånd och ta personligt ansvar. Publicerat 2020-04-01. Hämtad 2020-04-06. www.folkhalsomyndigheten.se  
  260. Folkhälsomyndigheten. Flera utbrott av covid-19 inom idrottslag och i samband med tävlingar. PUBLICERAT 22 SEPTEMBER 2020. www.folkhalsomyndigheten.se  
  261. Socialstyrelsen. Försäkringsmedicinskt beslutsstöd. Hämtad 2021-06-16.
  262. Folkhälsomyndigheten. Vägledning för användning av antigentester vid covid-19. Version 2, 2020-12-17. Hämtad 2021-01-16. medibas.se  
  263. Wei XS, Wang X, Niu YR, et al. Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19 published online ahead of print, 2020 Apr 17. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30526-7. PMID: 32311512 PubMed  
  264. Marquès M, Domingo JL. Contamination of inert surfaces by SARS-CoV-2: Persistence, stability and infectivity. A review. Environ Res. 2021;193:110559. doi:10.1016/j.envres.2020.110559 DOI  
  265. Socialstyrelsen. Statistik över antal avlidna i covid-19. Publicerad 2020-04-27. Hämtad 2020-04-27.
  266. World Health Organization, WHO. Situation reports, nr 64. Hämtad 2020-03-25 www.who.int  
  267. Folkhälsomyndigheten. Första resultaten om antikroppar efter genomgången covid-19 hos blodgivare. Publicerat 18 juni 2020. www.folkhalsomyndigheten.se  
  268. Det nya coronaviruset är en folkhälsofråga. Statens veterinärmedicinska anstalt. Uppdaterad 2020-06-13. Hämtad 2020-06-15. www.sva.se  
  269. Liu M, He P, Liu HG, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):209–214. PMID: 32164090. PubMed  
  270. Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. PREPRINT medRxiv
  271. Sahin U, Muik A, Derhovanessian E. Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. PREPRINT medRxiv
  272. Folegatti PM, Ewer KJ, Aley PK. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. DOI:https://doi.org/10.1016/S0140-6736(20)31604-4
  273. Zhu F-C, Guan X-H, Li Y-H. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Published: July 20, 2020. DOI:https://doi.org/10.1016/S0140-6736(20)31605-6
  274. Li R, Pei S, Chen B, Song Y et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science 16 Mar 2020: eabb3221 DOI: 10.1126/science.abb3221 DOI  
  275. Folkhälsomyndigheten. Rekommendationer till hälso- och sjukvårdspersonal samt laboratoriepersonal angående covid-19. Hämtad 2020-03-18 www.folkhalsomyndigheten.se  
  276. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and Possible Vertical Transmission published online ahead of print, 2020 Apr 18. Am J Perinatol. 2020;10.1055/s-0040-1710050. PMID: 32305046. PubMed  
  277. Folkhälsomyndigheten. Första resultaten från pågående undersökning av antikroppar för covid-19-virus. Publicerat 2020-05-20. Hämtat 2020-05-28. www.folkhalsomyndigheten.se  
  278. Hyperinflammation hos barn kan ha samband med covid-19. AC Horne, L Nordenhäll. Läkartidningen. 2020;117:20094
  279. Svensk barnreumatologisk förening. Utlåtande från Svensk barnreumatologisk förening till Barnläkarföreningen, BLF, angående Covid-19. Publicerad 2020-04-29. Hämtad 2020-05-06. medibas.se  
  280. European Centre for Disease Prevention and Control,An agency of the European Union. Novel coronavirus in China. Hämtad 2020-01-29. https://www.ecdc.europa.eu/en/novel-coronavirus-china
  281. WHO, Novel Coronavirus(2019-nCoV) Situation Report – 22 Hämtad 2020-02-12 www.who.int  
  282. Försäkringskassan. Coronaviruset – det här gäller. Uppdaterad 2020-07-08. Hämtad 2020-07-10.
  283. Regeringskansliet. Pressmeddelande: Smittbärarpenning till personer som bor med bekräftat smittade i covid-19. Publicerad 2020-10-02. Hämtad 2020-10-20. www.regeringen.se  
  284. Korea Centers for Disease Control & Prevention. Press release. www.cdc.go.kr  
  285. Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the Treatment of Covid-19 — Preliminary Report. The New England Journal of Medicine (NEJM). May 22, 2020DOI: 10.1056/NEJMoa2007764 DOI  
  286. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026. doi: 10.1136/bmj.m3026. PMID: 32784198. PubMed  
  287. COVID Symptom Study. How long does COVID-19 last? Kings College London, 2020. https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh_aI-
  288. Zhu FC, Li YH, Guan XH. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. May 22, 2020. doi.org  
  289. Leach S. Minst ett 70-tal möjliga vacciner mot sars-cov-2 är nu på gång. Medicinsk kommentar. Läkartidningen 2020;117:F3MZ. lakartidningen.se  
  290. Oxford University. Recovery, Randomized evaluation of Covid-19 therapy. 16 June 2020. www.recoverytrial.net  
  291. Siddiqi A, Hasan K. et al. COVID-19 Illness in Native and Immunosuppressed States: Clinical-Therapeutic Staging Proposal The Journal of Heart and Lung Transplantation, Volume 0, Issue 0 www.jhltonline.org  
  292. Folkhälsomyndigheten. Provtagningsindikation för nukleinsyrapåvisning vid covid-19, version 13. 2020-05-27. www.folkhalsomyndigheten.se  
  293. Folkhälsomyndigheten. Uppdrag för utökad diagnostik av covid-19. Nyhet 2020-03-31. Hämtad 2020-04-07.
  294. Svensson M. Behandling med 4-aminokinoliner vid covid-19 kan ge allvarliga biverkningar. Läkartidningen. 2020;117:F3UD.
  295. Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med 2020. doi:10.1056/NEJMp2005630 DOI
  296. Folkhälsomyndigheten. Provtagningsstrategi för covid-19. Hämtad 2020-03-18. www.folkhalsomyndigheten.se  
  297. McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate, hämtad 2020-03-19. www.uptodate.com  
  298. Tang X, Wu C, Li X. On the origin and continuing evolution of SARS-CoV-2. National Science Review 2020; nwaa036: Epub. doi:10.1093/nsr/nwaa036 DOI  
  299. Grein J, Ohmagari N, Shin D. Compassionate Use of Remdesivir for Patients with Severe Covid-19. The New England Journal of Medicine (NEJM). April 10, 2020. DOI: 10.1056/NEJMoa2007016 DOI  
  300. CDC. Pregnancy & Breastfeeding. Information about Coronavirus Disease 2019. 2020-03-17 (Hämtad 2020-03-17). www.cdc.gov  
  301. Folkhälsomyndigheten. Antal fall av covid-19. Hämtad 2020-03-20 www.folkhalsomyndigheten.se  
  302. FDA. CytoSorb® Approved by FDA for Emergency 300 mL Device Treatment of COVID-19. www.fda.gov  
  303. Folkhälsomyndigheten. Flera tecken på samhällsspridning av covid-19 i Sverige. 10 mars 2020 (Hämtad 2020-03-11). www.folkhalsomyndigheten.se  
  304. Socialstyrelsen. Prioritering inom intensivvård under extraordinära förhållanden. Mars 2020. Hämtad 2020-03-27. www.socialstyrelsen.se  
  305. Qifang Bi, Yongsheng Wu, Shujiang Mei, et al. Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts. medRxiv 2020. ePub ahead of print and peer-review. doi: https://doi.org/10.1101/2020.03.03.20028423 www.medrxiv.org  
  306. Baud D, QI X, Nielson-Saines, Musser D. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 2020 Published Online March 12, 2020 www.thelancet.com  
  307. Dong Y, Mo X, Hu Y et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics 2020:e20200702. doi:10.1542/peds.2020-0702 DOI  
  308. Le Bert, N., Tan, A.T., Kunasegaran, K. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature (2020). DOI: https://doi.org/10.1038/s41586-020-2550-z